Stoxline.com
android_stock_chart
Stock Chart

Stoxline Lite

Stoxline Pro

Option Calculator
Stoxline
Mobile

Home | Charts | Showcases | Stock Ranks | Options | ETFs | Educations

 
Tweet this page
Share on Facebook
Share on Google+

7 Binary Options

 

Enter Stock Symbol:  

Caladrius Biosciences- Inc. (CLBS)

3.95 -0.12 (-2.95%)

06-18 16:00

Open:

4.16

Pre. Close:

4.07

High:

4.15

Low:

3.95

Volume:

32,785

Market Cap:

38M

Stock Price Prediction (Update at 5:00pm est.)

If tomorrow:

Open lower

Open higher

High:

4.166 - 4.187

4.187 - 4.204

Low:

3.903 - 3.925

3.925 - 3.942

Close:

3.919 - 3.952

3.952 - 3.98

Technical analysis  (as of: 2018-06-18 4:25:34 PM)

Overall:

      

Stoxline rating system posted a NEUTRAL today, downgraded from higher rating. This stock seems to stay at current move trend, but it could change at anytime. So it is not a good time to buy or sell, stay at where you are until next BUY or SELL signal.

Target:

Six months: 4.75     One year: 4.98

Support:

Support1: 3.75    Support2: 3.12

Resistance:

Resistance1: 4.07    Resistance2: 4.26

Pivot:

3.95

Moving Averages:

MA(5): 4.01     MA(20): 3.98

MA(100): 4.56     MA(250): 4.09

MACD:

MACD(12,26): -0.07     Signal(12,26,9): -0.11

%K %D:

%K(14,3): 67.93     %D(3): 70.63

RSI:

RSI(14): 43.18

52-Week:

High: 6.35  Low: 2.63  Change(%): -10.2

Average Vol(K):

3-Month: 2658  10-Days 3489

Strong Sell ★★ Sell ★★★ Neutral ★★★★ Buy ★★★★★ Strong Buy

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
CLBS has closed above bottom band by 49.8%. Bollinger Bands are 57.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to CLBS's normal range. The bands have been in this narrow range for 24 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

2018-05-10T18:53:03-04:00
Caladrius Biosciences' (CLBS) CEO David Mazzo on Q1 2018 Results - Earnings Call Transcript

2018-05-10T16:09:07-04:00
Caladrius Biosciences beats by $0.15

2018-04-11T08:00:00-04:00
Your Daily Pharma Scoop: vTv Therapeutics Plunges, Spectrum Provides Updated Data, Selecta Sees Pullback On Data

2018-04-10T11:30:26-04:00
Caladrius Bio's CLBS12 nabs accelerated review status in Japan for critical limb ischemia

2018-03-22T18:39:06-04:00
Caladrius Biosciences' (CLBS) CEO David Mazzo on Q4 2017 Results - Earnings Call Transcript

2018-03-13T09:15:54-04:00
Japan-based study underway for Caladrius Bio's CD34 cell therapy in critical limb ischemia

2018-03-10T08:00:00-05:00
3 Things In Biotech, March 9: Amgen Rises, BioTime Advances, Caladrius Updates

2018-03-09T11:51:14-05:00
Your Daily Pharma Scoop: Progenics Rallies, Merck To Partner With Eisai, Teva Upsizes Debt Offering

Financial Analysis

Growth

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.

Profitability

Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.

Solvency

Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.

Efficiency

Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.

Click here to get more fundamental analysis.

 

Free Technical Analysis Charts

Stock Basics & Statistics

Sector:  Healthcare

Industry:  Biotechnology Medical Research

Shares Out. (M)

9.57

Shares Float (M)

1.71

% Held by Insiders

% Held by Institutions

5.40

Shares Short (K)

9

Shares Short Prior Month (K)

Stock Financials

EPS

-2.180

EPS Est. Current Year

-2.420

EPS Est. Next Year

-2.950

EPS Est. Next Quarter

-0.770

Forward EPS

1.#IO

Book Value (p.s.)

0.850

PEG Ratio

Profit Margin

Operating Margin

Return on Assets (ttm)

48.5

Return on Equity (ttm)

122.5

Qtrly Rev. Growth

Gross Profit (p.s.)

Sales Per Share

EBITDA (p.s.)

-1.418

Qtrly Earnings Growth

Operating Cash Flow (M)

Levered Free Cash Flow (M)

atoplab.com

Valuation

P/E

-1.81

P/E Growth Ratio

-0.03

P/BV

4.65

P/S

P/CF

Dividend Yield

Dividends & Splits

Dividend

Dividend Pay Date

Invalid DateTime.

Ex-Dividend Date

Invalid DateTime.

Forward Dividend

Last Split Date

Last Split Ratio

-1e+010

 

(c) 2006-2017 Stoxline.com | Contact us | NYSE, NASDAQ, AMEX Stock symbols

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.